14 May 2026

ASX Announcement

Leading neurotechnology pioneer Prof Nicholas Opie joins Control Bionics as Director and Strategic Advisor

Control Bionics Limited (ASX: CBL), a leader in neurotechnology and assistive communication solutions, today announced the appointment of Professor Nicholas Opie, one of Australia's leading neural-interface and medical device translation experts, as a Non-Executive Director and strategic advisor to the Company, effective 14 May 2026.

Prof Opie's appointment strengthens Control Bionics' technical, clinical and commercialisation capability as the Company advances its neuroelectric signal platform across assistive communication, sports performance, rehabilitation and broader neurotechnology applications.

Prof Opie is globally recognised for his work in brain-computer interface technology and the commercial translation of advanced bionics. He is a co-founder and director of Synchron Inc, the world's leading endovascular brain-computer interface company, Head of the Vascular Bionics Laboratory at the University of Melbourne and a founding director of ultrasonic deep-brain neuromodulation start-up, Ultra Bionics.

In addition to joining the Board, Prof Opie will work with Control Bionics' technical and clinical teams as a strategic advisor as the business continues to develop its platform.

Control Bionics Chairman Stephen Rix said Prof Opie's appointment was an important step in strengthening the Company's technical, clinical and strategic capability.

> "Nick is one of the most respected figures in neural interfaces and applied neurotechnology. His decision to join Control Bionics reflects the strength of the Company's science, the breadth of its potential applications and the opportunity to build a larger Australian neurotechnology business with global potential.
>
> "Nick brings deep technical, clinical and commercialisation experience to the business. He will work closely with the Board, management team and technical and clinical teams as we develop the next stage of Control Bionics' technology, use cases and market opportunity.
>
> "With Nick's experience creating life-changing medical technologies and founding commercial entities Synchron and Ultra Bionics to translate his work, his appointment reflects his broader interest in supporting Australian neurotechnology companies and the development of new technologies aimed at improving human function, communication and independence." Mr Rix said.

Prof Opie said:

> "Control Bionics has developed highly differentiated Australian technology with the potential to improve communication, independence and quality of life for people living with serious neurological and physical conditions. It has a strong scientific platform and an opportunity to extend its technology across important clinical and commercial use cases. I am excited to join the Board and support the team as it advances Australian-developed

assistive communication, rehabilitation, sports performance and broader neurotechnology applications for global markets."

In addition to his role as a Non-Executive Director, Prof Opie will be separately engaged as a strategic advisor on terms that sit alongside his Board fees.

Retirement of Non-Executive Director Dr Stephanie Phillips

The Company also announced that Dr Stephanie Phillips will retire as a Non-Executive Director, effective 14 May 2026.

Control Bionics Chairman Stephen Rix said:

> "On behalf of the Board, I would like to thank Stephanie for her service and her valuable medical, academic and governance contributions. Stephanie has supported the business through an important period of development and we are grateful for her commitment, judgement and contribution to the Company. We wish her every success for the future."

About Professor Nicholas Opie

Professor Nicholas Opie is a biomedical engineer and internationally recognised expert in neural interfaces, brain-computer interface technology and endovascular bionics. He is a founding director of Synchron and led the team behind the development of the Stentrode™ technology, a minimally invasive brain-computer interface designed to help people with paralysis control digital devices.

Prof Opie is also a founding director of Ultra Bionics, an early-stage deep-tech company developing implantable neurotechnology that can deliver high-resolution, steerable ultrasound to deep-brain regions, with a minimally-invasive surgical approach. This platform technology aims to aid those with neurological and neuropsychiatric conditions such as Parkinson's Disease, Epilepsy and Depression.

In addition, Nick is also Head of the Vascular Bionics Laboratory in the Department of Medicine at the University of Melbourne. His work has focused on translating advanced neurotechnology from research into clinical and commercial applications, including technologies designed to restore communication, independence and function for people with severe neurological and physical impairment.

Prof Opie has authored more than 60 peer-reviewed publications and filed more than 1090 patents across neural interfaces, endovascular sensing and stimulation, closed-loop ultrasonic neuromodulation, and brain-computer interface control systems.

His research has been published in leading journals including Nature Biotechnology, Nature Biomedical Engineering and JAMA Neurology, and his work has been recognised through the European Inventor Award, TIME Best Inventions, the NFMRI John Raftos AM Award for Advancing Innovation and the Innovation Aus Paul Shetler Disruptor of the Year Award.

This announcement has been authorised for release by the Board of Control Bionics Limited.

For further information, please contact:

Investors and Media:

Jeremy Steele – CEO and Managing Director
jsteele@controlbionics.com

Brett Crowley - Company Secretary
brettcrowley@controlbionics.com
For further information visit the website: https://www.controlbionics.com/

For Media enquiries:
Andrew Geddes
Seed Media
andrew@seedmedia.com.au
+61 008 677 734

Schedule 1 — Proposed Option Terms

Given Prof Opie's proposed contribution as a Director and strategic advisor, the Board has resolved to issue Prof Opie 1.25 million options, subject to shareholder approval at the Company's 2026 Annual General Meeting, to be held in October 2026.

The proposed options are intended to align Prof Opie's interests with Control Bionics shareholders and recognise the expected strategic value of his contribution to the Company's technology roadmap, clinical development and commercial growth strategy.

Terms	Details
Number of options	1.25 million
Exercise price	6.3c per share, being the closing price of CBL shares on the ASX on 13 May 2026
Vesting	312,500 options vesting on 13 May 2027
	312,500 options vesting on 13 May 2028
	312,500 options vesting on 13 May 2029
	312,500 options vesting on 13 May 2030
Expiry date	13 May 2031
Shareholder approval	The issue of options is subject to shareholder approval under ASX Listing Rule 10.11
Timing of issue	If shareholder approval is obtained at the 2026 Annual General Meeting, the options will be issued within seven days of approval

About Control Bionics:

Control Bionics Limited is a medical technology company commercialising assistive communication and neurotechnology products for people living with paralysis, loss of speech and other complex movement limitations. The Company's technology enables users to control digital devices using neuroelectric signals, spatial movement and other accessible control methods. Its current products include the NeuroNode® and NeuroStrip® platforms, assistive communication devices and emerging technologies for rehabilitation, sports performance and physiological monitoring.

About NeuroNode:

Our core patented NeuroNode technology is a wireless wearable device that detects minute signals sent from the brain to any skeletal muscle and is captured as EMG output. This output is then sent wirelessly via the NeuroNode to a personal computer, enabling speech and other computer-controlled functions like email and texting. Our technology is integrated with eye gaze technology whereby the eye gaze enables a cursor to be moved about a computer screen, driven much like a mouse, and the NeuroNode acts as like the mouse button. Control Bionics is the only

such product to harness three modalities – touch, eye and NeuroNode control – which combined yield unique benefits in terms of the ability of patients to express themselves with significantly faster speed and less fatigue.

About NeuroStrip:

Control Bionics is currently commercialising its most recent advancement in its technology, the NeuroStrip. This wearable, miniaturised EMG device provides the business with the opportunity to enter new markets such as health diagnostics, sports performance and rehabilitation to name only a few potential markets.

Control Bionics operates in North America, Australia, Europe and Japan.